Metabolic Cofactor Supplementation

DRUG2 trials

Sponsors

Istanbul Medipol University Hospital, ScandiBio Therapeutics AB

Conditions

Alzheimer DiseaseNon-alcoholic Fatty Liver Disease (NAFLD)Parkinson Disease

Phase 2

Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients

CompletedNCT04044131

Istanbul Medipol University HospitalAlzheimer Disease, Parkinson Disease

Start: 2019-12-02End: 2021-04-20Updated: 2022-08-08

Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease

CompletedNCT04330326

ScandiBio Therapeutics ABNon-alcoholic Fatty Liver Disease (NAFLD)

Start: 2019-07-20End: 2022-05-06Updated: 2025-02-10

Related Papers

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease

Alzheimer s Research & Therapy2025-03-117 citations

Multi-omics characterization of improved cognitive functions in Parkinson’s disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial

Brain Communications2024-12-24

Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

Translational Neurodegeneration2023-01-2669 citations